Journal of Experimental & Clinical Cancer Research (Jan 2021)

Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer

  • Liying Ma,
  • Xing Bian,
  • Wenchu Lin

DOI
https://doi.org/10.1186/s13046-020-01805-6
Journal volume & issue
Vol. 40, no. 1
pp. 1 – 1

Abstract

Read online

An amendment to this paper has been published and can be accessed via the original article.